Precision and Molecular Oncology:
Caring for Patients and Future Generations

March 1-2, 2024 | Rosewood Hotel, Abu Dhabi, UAE

Accredited for 8.5 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®)

Accredited by the Department of Health Abu Dhabi (DOH) for a maximum of 8.5 CME credits

Welcome Messages

Dear Colleagues,

Treating patients without fully understanding the established and emerging molecular biomarkers for cancer outcomes can limit many aspects of patient care. There are now several approved biomarkers that can help predict prognosis, select appropriate therapy and/or define eligibility for clinical trials, and monitor for cancer recurrence.

The WIN Symposium will provide attendees with deep understanding of the role of such biomarkers, their optimal application, and emerging new omic tests that will inform future biomarker adoption under the two big umbrellas of Precision Genomics and Precision Immunotherapy. Local experience from the UAE, the host country, will also be included to link global evidence to regional practice. The application of the principles of precision medicine will also be discussed beyond medical and onto radiation oncology. The symposium will also feature a Molecular Tumor Board to exemplify with real patient cases how to use biomarkers to inform therapeutic choices. Finally, a panel discussion will be dedicated to navigating available diagnostic pathways and tests from bench to bedside.

We hope you find this meeting educational and practice changing.

Prof. Wafik El-Deiry, MD PhD FACP
Chair, WIN Consortium
American Cancer Society Research Professor
Director, Legorreta Cancer Center
Associate Dean, Oncologic Sciences,
Warren Alpert Medical School, Brown University, RI, USA

Dear Colleagues,

It is our honor and pleasure to join efforts with the WIN Consortium to deliver this WIN Symposium in our beloved city of Abu Dhabi.

Under the theme of “Precision and Molecular Oncology: Caring for Patients and Future Generations,” this symposium aims to bring together expert clinicians, researchers, and industry professionals from around the world to discuss and explore the latest advancements in precision oncology.

The scientific and organizing committee have curated an exciting program that includes various interactive elements to illustrate the principles and best practices of applying precision medicine in treating cancer patients. We are eager to see an engaging dialogue between international scholars and innovators and local experts to bridge theory and real-world practice, both globally and as relevant to the local setting. The symposium will also feature networking opportunities, allowing participants to connect with peers, establish collaborations, and forge new partnerships.

Together, we can advance our understanding of cancer and work towards improving patient care, not only for the current but also for future generations.


Dr. Shamsheer Vayalil
Founder and Chairman,
Burjeel Holdings
Abu Dhabi, UAE

About WIN Consortium

Worldwide Innovative Network (WIN) Consortium is a non-profit association headquartered in France. The WIN network assembles 27 world-class academic medical centers, industries (pharmaceutical and diagnostic companies), research organizations and patient advocates spanning 18 countries and 5 continents, aligned to launch trials using its genomics and transcriptomics biomarker platform to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology. WIN was started by the late John Mendelsohn, President of MD Anderson Cancer Center, US and Thomas Tursz, Director General Gustave Roussy, France. The consortium has since then been led by Richard L. Schilsky, Chair Emeritus of WIN, Former Executive Vice-President & Chief Medical Offcer ASCO (2013-2021) and Professor Emeritus at the University of Chicago and Josep Tabernero, Vice-Chair of WIN, Head of Vall d’Hebron Institute of Oncology, Spain and Past-President ESMO. Most recently, Wafik El-Deiry, American Cancer Society Research Professor, Director Legoretta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, has been elected as Chair of WIN Consortium. Find more information at

About Burjeel Holdings

Founded in 2007, Burjeel Holdings is one of the leading private healthcare services providers in the MENA region. With a network of 68 assets, including 16 hospitals and 30 medical centers, as well as pharmacies and other allied services, the group provides the highest standard of patient care in the region. Burjeel Medical City, the flagship facility of Burjeel Holdings, is a 400-bed multi-specialty hospital and quaternary care center located in Abu Dhabi, UAE. It offers high-quality specialized treatment and complex care in over 40 adult and pediatric specialties, aided by state-of-the-art medical technology and an international team of experts. Burjeel Medical City is the latest member to the WIN Consortium & the first in the UAE to receive ESMO designation as an Integrated Oncology and Palliative Care Center. Find more information at |


Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Recognize established and emerging biomarkers with diagnostic, prognostic, or predictive value in contemporary cancer management
  • Learn best practices in using biomarker-based algorithms for cancer treatment selection, optimization, and monitoring
  • Understand design specifics and clinical implications of research studies and clinical trials assessing new biomarkers for immunotherapy and targeted therapy
  • Realize how principles of precision oncology can be applied to radiation therapy
  • Appreciate issues of access, diversity and equity in precision oncology practice and clinical trials

Target Audience

The target audience spans a wide range of high-profile stakeholders in clinical and non-clinical cancer research, technology development, and patient management who are interested to further their understanding of the role of biomarkers in cancer management. These could include:

  • Medical Oncologists
  • Hematologists
  • Surgical Oncologists
  • Radiation Oncologists
  • Pathologists
  • Laboratory Medicine Specialists
  • Pharmacists
  • Nurses
  • Clinical, Translational, and Basic Science Cancer Researchers
  • Government Officials Involved in Cancer Care and Control
  • Industry Officials Involved in Research and Development
Scroll to Top